News Center

News Center

Home page

Blog Center

News Center

Viwit Pharmaceuticals' Sterile Production Facility Successfully Passes U.S. FDA Inspection

Viwit Pharmaceutical's Phenylephrine Hydrochloride Injection Officially Receives Official Approval by China NMPA

Viwit Pharmaceuticals’ Brimonidine tartrate and Timolol maleate eye drops receive Official Approval by China NMPA

Viwit's Nitroglycerin Sublingual Tablets Approved by FDA

Viwit Pharmaceuticals API Site Successfully Passed FDA cGMP On-site Audit with "No Action Indicated"

Viwit Pharmaceutical Co. Ltd. announces exclusive licensing and supply agreement for two Gadolinium based Magnetic Resonance Imaging (MRI) injectable contrast agents in the US.

CPhI India 2018, Booth No. 4.H15

Author：

Release Time：

2018-12-12

CPhI India 2018, Booth No. 4.H15

CPhI India 2018 will take place on Dec. 12 - Dec. 14, 2018 at India Expo Center, India. Please visit us on CPhI India 2018, Booth No. 4.H15. If you would like to make an appointment, please send an e-mail to service@viwit.com.

Previous

Welcome participants in CPhI India 2018, booth number: 4.H15

Next

VIWIT

Technical Support:China Enterprise Cross-border | SEO Tags

【Business License】

Search